Overcoming key challenges in cancer immunotherapy with engineered T cells

Arcangeli S, Mestermann K, Weber J, Bonini C, Casucci M, Hudecek M (2020)

Publication Type: Journal article, Review article

Publication year: 2020

Journal

Current Opinion in Oncology Lippincott, Williams & Wilkins

Book Volume: 32

Pages Range: 398-407

Journal Issue: 5

DOI: 10.1097/CCO.0000000000000664

Abstract

Purpose of review A number of clinical trials are currently testing chimeric antigen receptor (CAR) and T cell receptor (TCR) engineered T cells for the treatment of haematologic malignancies and selected solid tumours, and CD19- CAR-T cells have produced impressive clinical responses in B-cell malignancies. Here, we summarize the current state of the field, highlighting the key aspects required for the optimal application of CAR and TCRengineered T cells for cancer immunotherapy. Recent findings Toxicities, treatment failure and disease recurrence have been observed at different rates and kinetics. Several strategies have been designed to overcome these hurdles: the identification and combination of known and new antigens, together with the combination of immunotherapeutic and classical approaches may overcome cancer immune evasion. New protocols for genetic modification and T cell culture may improve the overall fitness of cellular products and their resistance to hostile tumour immunomodulatory signals. Finally, the schedules of T cell administration and toxicity management have been adapted to improve the safety of this transformative therapeutic approach. Summary In order to develop effective adoptive T cell treatments for cancer, therapeutic optimization of engineered CAR and TCR T cells is crucial, by simultaneously focusing on intrinsic and extrinsic factors. This review focuses on the innovative approaches designed and tested to overcome the hurdles encountered so far in the clinical practice, with new excitement on novel laboratory insights and ongoing clinical investigations.

Involved external institutions

Ospedale San Raffaele (früher: Centro San Raffaele del Monte Tabor Foundation) IT Italy (IT) Universitätsklinikum Würzburg DE Germany (DE) Università Vita-Salute San Raffaele (UniSR) IT Italy (IT)

How to cite

APA:

Arcangeli, S., Mestermann, K., Weber, J., Bonini, C., Casucci, M., & Hudecek, M. (2020). Overcoming key challenges in cancer immunotherapy with engineered T cells. Current Opinion in Oncology, 32(5), 398-407. https://doi.org/10.1097/CCO.0000000000000664

MLA:

Arcangeli, Silvia, et al. "Overcoming key challenges in cancer immunotherapy with engineered T cells." Current Opinion in Oncology 32.5 (2020): 398-407.

BibTeX: Download